Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Amicus Therapeutics (FOLD) Tops Q1 EPS by 5c, Misses on Revenue
May 1, 2025 7:06 AM EDT(Updated - May 1, 2025 10:00 AM EDT)
Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of $0.03, $0.05 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $125.25 million versus the consensus estimate of $136.65 million.
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.
... More